VVY — Vivoryon Therapeutics NV Cashflow Statement
0.000.00%
- €42.80m
- €33.48m
Annual cashflow statement for Vivoryon Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.5 | -12.2 | -28.2 | -28.3 | -20.6 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.688 | 1.37 | 6.15 | 6.78 | 2.42 |
Other Non-Cash Items | |||||
Changes in Working Capital | 1.66 | -0.565 | 0.246 | 0.091 | -1.17 |
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -14 | -11.3 | -21.8 | -21.5 | -19.2 |
Capital Expenditures | -0.064 | -0.028 | -0.013 | -0.514 | -0.002 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.576 | — | — | -10 | 10 |
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.64 | -0.028 | -0.013 | -10.5 | 10 |
Financing Cash Flow Items | 0 | -1.88 | -2.53 | -2.1 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.09 | -0.827 | 33.4 | 24.2 | -0.057 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -15.2 | -11.6 | 11.9 | -7.99 | -9.2 |